Detail akcie Nicox online

Business Summary: Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2022, NicOx SA revenues decreased 55% to EUR3.3M. Net loss decreased 37% to EUR27.8M. Revenues reflect Revenue from collaborations decrease of 39% to EUR5.2M, Royalty payments decrease of 46% to -EUR2M. Lower net loss reflects Impairment of intangible assets decrease of 61% to EUR10.9M (expense), Financial Expense - Other - Balancing va decrease of 86% to EUR387K (expense).